Dynavax (DVAX) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dynavax Reports First Quarter 2022 Financial Results
May 5, 2022 4:02 PM EDTFirst quarter 2022 total revenue of $114.0 million, up 37% from $83.3 million for Q1 2021HEPLISAV-B® vaccine net product revenue of $20.8 million, up 151% from $8.3 million for Q1 2021CpG 1018® adjuvant net product revenue of $91.5 million, up 23% from $74.6 million for Q1 2021Guidance reiterated for 2022 CpG 1018 revenue, operating expenses, and other costsOn track for a second consecutive year of profitabilityConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., May 5, 2022 /PRNewswire/ --... More
